Frequency and risk factors for thrombosis in idiopathic myelofibrosis: Analysis in a series of 155 patients from a single institution

Leukemia

Volumn 20, Issue 1, 2006, Pages 55-60

  Cervantes, F ^a   Alvarez Larran A ^a   Arellano Rodrigo, E ^a   Granell, M ^a   Domingo, A ^a   Montserrat, E ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Idiopathic myelofibrosis; Myelofibrosis with myeloid metaplasia; Thrombosis

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; CALCITRIOL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; ERYTHROPOIETIN; HEMOGLOBIN; HYDROXYUREA; MERCAPTOPURINE; OXYMETHOLONE;

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DOPPLER ECHOGRAPHY; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; POPULATION DISTRIBUTION; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; RISK FACTOR; SMOKING HABIT; SPAIN; SPLENECTOMY; SPLENOMEGALY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOSIS; VEIN THROMBOSIS;

EID: 33644987043     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404048     Document Type: Article

References (27)

1. Gruppo Italiano Studio Policitemia. Polycythemia vera: The natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656-664.
2. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Patrono C, Barbui T. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 35: 114-124.
3. Cortelazzo F, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F et al. Hydroxyurea for patients with essential thrombocythemia and high risk of thrombosis. New Engl J Med 1995; 332: 1132-1136.
4. Besses C, Cervantes F, Pereira A, Florensa L, Solé F, Hernández-Boluda JC et al. Major vascular complications in essential thrombocythaemia: A study of the predictive factors in a series of 148 patients. Leukemia 1999; 13: 150-154.
5. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33-45.
6. Brodmann S, Passweg JR, Gratwohl A, Tichelli A, Skoda RC. Myeloproliferative disorders: Complications, survival and causes of death. Ann Hematol 2000; 79: 312-318.
7. Ganti AK, Potti A, Koka VK, Pervez H, Mehdi SA. Myeloproliferative syndromes and the associated risk of coronary artery disease. Thrombos Res 2003; 110: 83-86.
8. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: A single-institution experience with 223 patients. Blood 2000; 95: 2226-2233.
9. Akpek G, McAneny D, Weintraub L. Risks and benefits of splenectomy in myelofibrosis with myeloid metaplasia: A retrospective analysis of 26 cases. J Surg Oncol 2001; 77: 42-48.
10. Loring LA, Panicek DM, Karpeh MS. Portal system thrombosis after splenectomy for neoplasm or chronic hematologic disorder: Is routine surveillance imaging necessary? J Comput Assist Tomogr 1998; 22: 856-860.
11. Fujita F, Lyass S, Otsuka K, Giordano L, Rosenbaum DL, Khalili TM et al. Portal vein thrombosis following splenectomy: Identification of risk factors. Am Surg 2003; 69: 951-956.
12. Najean Y, Dresch C, Rain JD. The very long-term course of polycythemia: a complement to the previously published data of the Polycythemia Vera Study Group. Br J Haematol 1994; 86: 233-235.
13. Cervantes F, Alvarez-Larrán A, Talarn C, Gómez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: Actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 2002; 118: 786-790.
14. Thiele J, Kvasnicka HM, Boeltken B, Zankovich R, Diehl V, Fischer R. Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) - a clinicopathological study. Leukemia 1999; 13: 1741-1748.
15. Barosi G, Ambrosetti A, Finelli G, Grossi A, Leoni P, Liberato NL et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol 1999; 104: 730-737.
16. Lennert K, Naghai K, Schwarze EW. Patho-anatomical features of the bone marrow. Clin Haematol 1975; 43: 331-351.
17. Fowkes FGR, Housley E, Cawood EHH, Macintyre CCA, Ruckley CV, Prescott RJ. Edinburgh artery study: Prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384-392.
18. Stewart JA, Dundas R, Howard RS, Rudd AG, Wolfe CDA. Ethnic differences in incidence of stroke: Prospective study with stroke register. Br Med J 1999; 318: 967-971.
19. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, ÓFallon M et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452-463.
20. Lampe FC, Morris RW, Walker M, Shaper GA, Whincup PH. Trends in rates of different forms of diagnosed coronary heart disease, 1978 to 2000: prospective, population based study of British men. Br Med J 2005; 330: 1046-1049.
21. Cervantes F, Pereira A, Esteve J, Rafel M, Cobo F, Rozman C. et al. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997; 97: 635-640.
22. Falanga A, Marchetti M, Evangelista V, Manorini S, Oldani M, Giovanelli S et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96: 4261-4266.
23. Alvarez-Larrán A, García-Pagan JC, Abraldes JG, Arellano E, Reverter JC, Bosch J et al. Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. Br J Haematol 2004; 124: 329-335.
24. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
25. Kralowics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
26. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005; 434: 1144-1148.
27. Levine RL, Wadleigh M, Cools J, Eber BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.